Research programme: PARP-1 inhibitors - Rocket/University of Pittsburgh
Alternative Names: INH2BP; PARP-1 inhibitorLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Inotek Pharmaceuticals; University of Pittsburgh
- Class Neuroprotectants
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 04 Jan 2018 Rocket Pharmaceuticals merged with Inotek Pharmaceuticals and the combined company was named Rocket Pharmaceuticals
- 04 Aug 2006 No development reported - Preclinical for Neurological disorders (Prevention) in USA (unspecified route)
- 12 Sep 2003 This compound is still in active development